Member Info for BOJO2020

Thanks Mia and Chester18

Absolutely spot on Chester with your first paragraph re: testing and validation of AvidiMab in different applications. The type of deals will reflect this I suppose.

What do the broker notes suggest? For a cross reference

*ramper you

TGTD

To clarify your point; which I take to indicate an excellent route to market…

An accredited lab can use a Parsortix device using a test that they develop and validate. So Angle sell a device and most likely more than one so that the amount of tests carried out are meaningful £🤩$👍€. And they would of course need consumables at £300 a pop.

Oh you tamper you 😅

Well Angle could be accused of diving into many a rabbit hole but this one could lead to wonderland?!

Thanks Thompi for the link. Personally I think it is right on the money and seems to be where Angle are headed.

Look at OBD, POLX, RENE, ANGLE. All need to commercialise! They all have outstanding tests/device but they have to match these to the needs of customers, end users, and patients. No point having a test if it is not useable! So I am afraid that anybody complaining that FDA did not equal instant sales was either unaware of the reality of getting product's, test or devices to market. The common denominator is lack of awareness, knowledge and experience and I am afraid that is the responsibility solely of the investor. So there really is no point blaming the companies...

Truth hurts I am afraid but many will learn for next time.

I would say why quit now when the hard work is pretty much done?

The FDA was indeed a highlight, however looking at the Proactive One2One presentation things have moved on to bring the Parsortix device closer to the end user. We all have an opinion on how close that is, and knowing SK as we do I'd say he would be objective in his analysis as always. I am pretty sure he recognises what has appeared to be a baron period for Angle over the last 18 months was in fact a preparatory period in which the seeds have been sown. Now all we need to do is reap the harvest.

Thinking about a point I made earlier. Checkpoint inhibitors are not suitable or effective for all patients. But, if iSCIB1+ does what is expected then a whole lot more people (than SCIB1 40%) will get the benefit. Now just for perspective this am I have watched a presentation by a CTC capture company and read an RNS on a checkpoint inhibitor test company who would argue that 1. each patients cancer is different 2. each patient is different and 3. each patients tolerance to different drugs is different. In fact these critical questions apply across the board. Fascinating then to see how the SCOPE trial fairs with these three question! In its SCIB1 guise it was indeed, encouraging, promising and exceptional it appears ratcliifewriter. Hopeful for iSCIB1+ but we cannot really hope for 85% ORR can we? Although I have everything crossed!

Well it occurs to me that SCIB1 may well be reinventing CPI's. Especially if the CIRT test takes hold and the use of CPI's becomes more focused. That could lead to a reduction in the use of CPI's by as much as 70%

AN spotted photo bombing Fusion Anti Bodies presso. That boy loves the spotlight

Abingdon Health just uploaded by Proactive One2One on YouTube. Expect Angle shortly...

Imminently even 😅

Jolly,

LTIP triggered at 25.75...

I reckon staff and execs will go for 45p to maximise

Don't forget the delayed action 3 years

Why wouldn't Angle just go for it around 50p? Then they can raise. Far less dilutitive at those levels so not in the slightest concerned old bean!

TGTD,

Any FDA approved device MUST state for research use purposes only. Please check with FDA

Sorry Thompi I misunderstood. I was talking about fairly immediate share price movement. I think all four companies will not be receiving a bid until they are further de-risked. I don't see a buy out for any of them for at least 12 to 18 months. My point is that anybody investing could see a good return on investment as the shares in issue are very reasonable and the prospects are good, and these companies have head room to raise.

I would of course encourage anyone reading this to do their own research and make their own decisions

Hi Thompi,

Shares in issue are 260m so absurd share price spikes are a real possibility to any quality company with good prospects. That includes Angle, OBD, even POLX and RENE could go on a run. And because of sensible share issued, all of these companies have head room to raise if required and still have good runs imo. Investors are looking for the next OBD which hit 55p from 10p levels in late 23. That appears to be Angle in early 24 and I do think it has further to climb again before settling down. Then I guess it will be POLX?

Https://www.lse.co.uk/rns/breakthrough-clinical-results-b0km788ah9aflqm.html

Which led to a 212% spike

Still 70% up a week later

Don’t take my word for it. Explore the list of RNS’s

And!

On that note, please take a look at the RNS feed. A chronological list of factual achievement.

Bring on the clown 🤡

Thanks grange 🙂

My take on the loonies. They put Angle among the top LSE chat. Therefore people come and take a look at what the fuss is all about and discover Angle.

Can’t be bad…

Bobbust,

As always appreciate the effort

ATB